Alberto Hernández1, Montserrat Viñals2, Asunción Pablos2, Francisco Vilás3, Peter J Papadakos4, Duminda N Wijeysundera5, Sergio D Bergese6, Marc Vives7. 1. Department of Anesthesiology & Perioperative Medicine, Policlinica Ibiza Hospital, Ibiza, Spain. 2. Department of Internal Medicine, Policlinica Ibiza Hospital, Ibiza, Spain. 3. Department of General Surgery, Policlinica Ibiza Hospital, Ibiza, Spain. 4. Department of Intensive Care Medicine, University of Rochester, Rochester, NY, USA. 5. Department of Anesthesiology & Perioperative Medicine, St Michael Hospital, Toronto, Canada. 6. Departments of Anesthesiology & Neurological Surgery, Stony Brook University, Stony Brook, NY, USA. 7. Department of Anesthesiology & Perioperative Medicine, Hospital Universitari de Girona Dr J Trueta, Girona, Spain. Electronic address: mvives.girona.ics@gencat.cat.
Abstract
BACKGROUND: There is still no specific treatment strategies for COVID-19 other than supportive management. DESIGN: A prospective case-control study determined by admittance to the hospital based on bed availability. PARTICIPANTS: Eighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration. MAIN OUTCOMES: The primary outcome was time from hospital admission to clinical improvement. RESULTS: Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p = 0.04) and better outcomes at 14-days (88.8% vs 33.3%, p = 0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p = 0.04, 95% CI -22.25 to -0.42). CONCLUSION: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials. CLINICAL TRIAL REGISTRATION NUMBER: NCT04444531.
BACKGROUND: There is still no specific treatment strategies for COVID-19 other than supportive management. DESIGN: A prospective case-control study determined by admittance to the hospital based on bed availability. PARTICIPANTS: Eighteen patients with COVID-19infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration. MAIN OUTCOMES: The primary outcome was time from hospital admission to clinical improvement. RESULTS: Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p = 0.04) and better outcomes at 14-days (88.8% vs 33.3%, p = 0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p = 0.04, 95% CI -22.25 to -0.42). CONCLUSION: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials. CLINICAL TRIAL REGISTRATION NUMBER: NCT04444531.
Authors: Marcos Edgar Fernández-Cuadros; María Jesús Albaladejo-Florín; Sandra Álava-Rabasa; Juan Gallego-Galiana; Gerardo Fabiel Pérez-Cruz; Isabel Usandizaga-Elio; Enrique Pacios; David E Torres-García; Daiana Peña-Lora; Luz Casique-Bocanegra; María Jesús López-Muñoz; Javier Rodríguez-de-Cía; Olga Susana Pérez-Moro Journal: SN Compr Clin Med Date: 2021-03-22
Authors: Alessandro de Sire; Francesco Agostini; Lorenzo Lippi; Massimiliano Mangone; Simone Marchese; Carlo Cisari; Andrea Bernetti; Marco Invernizzi Journal: Biomolecules Date: 2021-02-26
Authors: Amato De Monte; Giovanni Sermann; Emanuela Sozio; Francesco Sbrana; Carlo Tascini Journal: Intern Emerg Med Date: 2021-02-03 Impact factor: 3.397
Authors: Emanuela Sozio; Amato De Monte; Giovanni Sermann; Flavio Bassi; Davide Sacchet; Francesco Sbrana; Andrea Ripoli; Francesco Curcio; Martina Fabris; Stefania Marengo; Daniele Italiani; Daniela Luciana Boccalatte-Rosa; Carlo Tascini Journal: Int Immunopharmacol Date: 2021-06-12 Impact factor: 5.714